<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922181</url>
  </required_header>
  <id_info>
    <org_study_id>kulasMWA1</org_study_id>
    <nct_id>NCT00922181</nct_id>
  </id_info>
  <brief_title>Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer</brief_title>
  <acronym>LiverMWA1</acronym>
  <official_title>Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microwave ablation (MWA) is the most recent development in the field of local ablative
      therapies. The aim of this study was to evaluate the variability and reproducibility of
      single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller
      than 3 cm in patients without underlying liver disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variability of ablation diameters</measure>
    <time_frame>within the first 7 days and 3 months after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>MWA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave ablation</intervention_name>
    <description>Liver tumors are destructed/ablated using single-probe microwave energy device</description>
    <arm_group_label>MWA</arm_group_label>
    <other_name>MW ablation antenna (VT2237) and a 915 MHz Valleylab MW generator (VTSYS3; Covidien, Europe NV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Liver tumors are destructed/ablated using radiofrequency energy device</description>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable metastatic liver cancer

          -  No invasion of major biliary structures

          -  No invasion of major vascular structures

          -  ASA score &lt; 4

          -  WHO score 0-1

          -  Pre-operative chemotherapy is allowed

        Exclusion Criteria:

          -  Resectable liver metastases

          -  Life expectancy less than 3 months

          -  Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic
             instruments or other metal materials

          -  Coagulopathy with platelet count less than 50000

          -  Active infectious disease

          -  Age below 18 years

          -  Pregnancy of breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baki Topal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>November 13, 2009</last_update_submitted>
  <last_update_submitted_qc>November 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>University Hospital Gasthuisberg Leuven</name_title>
  </responsible_party>
  <keyword>malignancy</keyword>
  <keyword>liver</keyword>
  <keyword>microwave</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

